Disclaimer:All content on this platform is sourced from the internet and is provided for informational purposes only. None of the content represents the views of this site, nor does it constitute investment advice. Please exercise caution when investing.
Weight-loss drug stocks saw broad gains, with Arrowhead Pharmaceuticals rising more than 16%, Novo Nordisk up over 4%, and Eli Lilly and Pfizer each up more than 2%.
Weight-loss drug stocks saw broad gains, with Arrowhead Pharmaceuticals rising more than 16%, Novo Nordisk rising more than 4%, and Eli Lilly and Pfizer rising more than 2%.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice. If you find any violations, please Click to Report
Recommended Reading


